College of Medicine
Wang Lab
Led by Gary Wang · Medicine
What we study
The Wang Lab studies how gut microbes protect against Clostridioides difficile infections using gnotobiotic mice, metagenomics, and metabolomics. They aim to develop defined microbial consortia for therapeutic use.
What working here is like
- Wet lab
- Computational
- Mice
- Bacteria & microbes
- Coding helps
- Projects
- 2
- Papers
- 5
Current projects
Microbial Metabolites in Host Defense
They study how gut microbes transform bile acids and amino acids to create environments hostile to pathogens.
Project Investigating Suspended Bacterial Aggregates in Commensal Gut Microbiota
The lab studies how gut bacteria form suspended aggregates versus planktonic cells. Students will use a simple method to separate and count bacteria in mouse gut samples, measuring the proportion of aggregates in healthy mice and in models of Clostridioides difficile infection.
From the Spring 2025 UF Undergraduate Research Symposium · abstract book, p. 517
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- Association of SARS-CoV-2 infection with incident diabetes among U.S. Veterans in a prospective longitudinal cohort
2026 · PLoS ONE
Looks at whether COVID-19 raises diabetes risk in veterans.
- Vancomycin Taper and Pulse or Fidaxomicin for Recurrent C. difficile Infection
2026 · NEJM Evidence
Tests two new antibiotic treatments for recurrent C. difficile infections.
Show 3 more papersShow fewer
- Colonization resistance against Clostridioides difficile is a graded, microbiota-intrinsic property of healthy human gut communities
2026 · ISME Host Microbe
Shows how different gut bacteria protect against C. difficile infections.
- 549. A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia
2026 · Open Forum Infectious Diseases
Trials a new phage therapy for severe staph infections.
- Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial
2026 · The Lancet HIV
Sees if a cholesterol drug lowers high blood pressure in people with HIV.
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Gary Wang hasn't set up this page yet. You can also look them up in the UF directory (search “Gary Wang”).